You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at S&P Capital IQ Pro or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Bristol-Myers' Opdivo gets US FDA approval for colorectal cancer
Gauging Supply Chain Risk In Volatile Times
Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals
The Future of Risk Management Digitization in Credit Risk Management
Climate Credit Analytics: Diving into the model
The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co.'s Opdivo in another cancer indication.
The therapy can now be used to fight a certain type of metastatic colorectal cancer that progressed after receiving fluoropyrimidine, oxaliplatin and irinotecan.
The indication was approved under accelerated approval supported by overall response rate and duration of response in a phase 2 trial.
Opdivo is approved for a number of cancers, including lung cancer.